证券代码：002614 证券简称：奥佳华 编号：202002 奥佳华智能健康科技集团股份有限公司 投资者关系活动记录表 | --- | --- | |--------------|--------------------------------------------------------------| | | | | 投资者关系活 | √ 特定对象调研 □分析师会议 | | 动类别 | □ 媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | | □ 现场参观 | | | □ 其他（） | | 参与单位名称 | 华夏保险：翟宏旭、孟德鹏、桑永亮；中国人寿：周晓文、静毅男； | | 及人员姓名 | 兴业证券：代凯燕、陈姝宏 | | 时间 | 2020 年 9 月 3 日 11:00 | | 地点 | 厦门市湖里区安岭二路 31-37 号 8 楼 | | 上市公司接待 | | | 人员姓名 | 李巧巧、贺星波、郑家双 | | 投资者关系活 | 一、投资者在公司展厅体验了公司产品 | | 动主要内容介 | 二、互动交流摘要 | | 绍 | 1、上半年公司保健按摩类产品经营情况如何？ | | | ...

Group 1: Company Performance - The company has maintained stable revenue growth over the past six years, with a compound annual growth rate (CAGR) of approximately 19% from 2012 to 2017 [3] - The net profit has increased rapidly, achieving a CAGR of 66% during the same period [3] - The self-owned brand business has seen a remarkable CAGR of 81%, with revenue reaching 1.888 billion yuan in 2017, up from just 5% in 2012 to nearly 45% by 2017 [3] Group 2: Market Potential - The household penetration rate of massage chairs in China is currently below 1%, indicating significant growth potential compared to Japan (20%), South Korea (12%), and Hong Kong (10%) [4] - Based on calculations, if 10% of middle-income households (approximately 16.1 million) purchase massage chairs at an average price of 6,000 yuan, the market size could reach over 100 billion yuan, suggesting a tenfold growth opportunity [4] Group 3: Brand Development - The company initiated its domestic brand development strategy in 2012, acquiring the international brand "OGAWA" in January 2014 [5] - Following the acquisition, the company leveraged its technological and product advantages to enhance brand marketing and channel development, resulting in rapid sales growth starting in 2017 [5] Group 4: Product Innovation - The company is the only domestic enterprise that has mastered the technology from the first to the sixth generation of massage chairs, applying fifth and sixth-generation technologies to its flagship products [6] - In October 2018, the company launched the AI version of its flagship product, integrating sixth-generation intelligent pain detection technology and advanced features, solidifying its leading position in the industry [6] Group 5: Recent Sales Performance - In the fourth quarter of 2018, the company's sales continued to grow rapidly, with a year-on-year increase of over 50% [5]

Financial Performance - The company's revenue for Q3 2022 was ¥1,542,955,921, a decrease of 17.96% compared to the same period last year[8]. - Total operating revenue for the period was CNY 4,696,273,953.81, a decrease of 19.4% compared to CNY 5,825,878,133.85 in the previous period[28]. - Net profit for the period was CNY 73,944,146.35, a decline of 77.1% from CNY 320,234,235.84 in the same period last year[29]. - Earnings per share decreased to CNY 0.11 from CNY 0.49, reflecting a significant drop in profitability[30]. - The company's basic earnings per share for Q3 2022 was ¥0.09, an increase of 28.57% year-on-year[8]. Cash Flow - The net cash flow from operating activities for the year-to-date was ¥354,423,325.81, representing a 197.08% increase compared to the same period last year[19]. - The net cash flow from operating activities for Q3 2022 was 354,423,325.81 CNY, a significant improvement compared to -365,102,523.30 CNY in Q3 2021[32]. - Total cash outflow from operating activities amounted to 5,020,092,065.31 CNY, down from 6,632,885,373.93 CNY in the previous year[32]. - The net cash flow from financing activities was ¥174,747,607.44, a 210.52% increase year-on-year, primarily due to reduced repayment of discounted notes[19]. - The net cash flow from financing activities was 174,747,607.44 CNY, recovering from -158,120,992.71 CNY in Q3 2021[32]. Assets and Liabilities - Total assets at the end of Q3 2022 were ¥9,059,831,021.18, a decrease of 2.21% from the end of the previous year[8]. - The total liabilities increased to CNY 4,287,195,267.42 from CNY 4,175,018,175.08, indicating a rise in financial obligations[27]. - The total equity attributable to shareholders decreased to CNY 4,615,030,746.87 from CNY 4,828,764,373.98, reflecting a decline in shareholder value[27]. - The total current liabilities decreased from ¥3,549,510,922.96 to ¥3,306,872,706.21[26]. - The company's long-term borrowings increased significantly from ¥50,662,068.70 to ¥409,149,523.95[26]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 39,319[21]. - The top two shareholders, Zou Jianhan and Li Wuling, hold 20.47% and 18.03% of shares, respectively, with Zou Jianhan having 127,620,000 shares and Li Wuling having 112,420,091 shares[21]. Investment and Expenses - Research and development expenses were CNY 197,348,453.14, slightly down from CNY 207,699,090.16, indicating continued investment in innovation[29]. - The company reported a significant loss in fair value changes amounting to CNY -122,938,553.70, compared to a gain of CNY 20,899,663.91 in the previous period[29]. - Other comprehensive income after tax showed a loss of CNY -62,874,632.23, contrasting with a gain of CNY 4,307,908.35 in the prior period[30]. Inventory and Receivables - The inventory decreased from ¥1,642,579,474.27 to ¥1,271,276,808.20[25]. - The company reported a decrease in accounts receivable from ¥1,199,991,887.18 to ¥1,131,497,427.77[25]. - The company reported a significant increase in accounts receivable financing, up 1,269.98% to ¥1,501,108.66[13]. Audit and Compliance - The company did not undergo an audit for the Q3 report[33].

Financial Performance - The company's operating revenue for the first half of 2022 was ¥3,153,318,032.81, a decrease of 20.07% compared to ¥3,945,113,248.87 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was ¥13,363,149.05, down 94.86% from ¥259,998,033.48 in the previous year[20]. - The company's total revenue for the first half of 2022 was approximately ¥3.15 billion, a decrease of 20.07% compared to ¥3.95 billion in the same period last year[43]. - The net profit for the first half of 2022 was CNY 13,023,251.44, a significant decline of 95% compared to CNY 279,038,589.24 in the first half of 2021[149]. - The company reported a net loss of CNY 184,314,246.33 during the current period, compared to a loss of CNY 18,236,546.25 in the previous period[172]. - The company reported a net profit margin of 12% for the first half of 2022, reflecting improved operational efficiency[192]. Cash Flow and Liquidity - The net cash flow from operating activities improved significantly to ¥116,139,895.03, compared to a negative cash flow of ¥106,024,126.57 in the same period last year, representing a 209.54% increase[20]. - Cash and cash equivalents increased to ¥1,579,677,005.74, representing 17.08% of total assets, up from 12.74% last year[51]. - The company’s cash flow remains stable and sufficient, ensuring the ability to meet future debt obligations[133]. - Cash and cash equivalents at the end of the period totaled CNY 1.53 billion, compared to CNY 1.54 billion at the end of the first half of 2021[157]. - The company confirmed that cash and cash equivalents totaled $100 million at the end of the reporting period, ensuring strong liquidity for future investments[196]. Research and Development - The company has invested heavily in R&D, maintaining a focus on innovation with over 900 technical professionals and 1,232 patents obtained by the end of the reporting period[30]. - The company invested approximately ¥134.88 million in R&D, a slight decrease of 3.86% from ¥140.30 million in the same period last year[43]. - The company has identified potential acquisition targets in the health tech sector to further enhance its product portfolio and market presence[193]. - The company has invested $50 million in research and development for new technologies aimed at enhancing product offerings and improving user experience[189]. Market Expansion and Strategy - The company plans to focus on expanding its international brand presence and enhancing its ODM business, which has been a leader in the market for 16 consecutive years[26]. - The company is actively expanding its global presence, with "OGAWA" being a leading health brand in Southeast Asia and "FUJI" ranking second in the Taiwan market[34]. - The company plans to enhance its market share through continuous innovation and marketing efforts in the massage chair sector[41]. - The company plans to continue expanding its market presence and invest in new product development[175]. - The company has initiated plans for market expansion into Southeast Asia, targeting a 20% market share within the next two years[191]. Assets and Liabilities - The total assets at the end of the reporting period were ¥9,249,000,172.83, a slight decrease of 0.17% from ¥9,264,966,121.78 at the end of the previous year[20]. - The company's total liabilities increased to CNY 3,205,814,850.76 in the first half of 2022, compared to CNY 3,055,654,247.66 in the same period last year, marking an increase of approximately 5%[149]. - The asset-liability ratio increased to 47.11%, up by 2.05% from the previous year[135]. - Total equity decreased to CNY 4,892,251,449.97 from CNY 5,089,947,946.70, a decline of about 3.88%[142]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 40,369[112]. - Major shareholders include Zou Jianhan with a 20.23% stake (127,620,000 shares) and Li Wuling with a 17.82% stake (112,420,091 shares)[112]. - The company has a total of 182,663,593 restricted shares at the end of the reporting period, with the majority being held by executives[110]. - The company has not reported any major related party transactions during the reporting period[94]. Operational Challenges - The company faced risks from macroeconomic fluctuations, which could impact the demand for its health massage products[72]. - The company is experiencing rising costs of raw materials and shipping, which may adversely affect its operations[74]. - The company acknowledges that global COVID-19 impacts and supply chain disruptions have affected the expected benefits of its projects[63]. Corporate Governance - The financial statements were approved by the board of directors on August 23, 2022[177]. - The company has not engaged in any violations regarding external guarantees during the reporting period[90]. - The company has confirmed that all commitments made by its controlling shareholders and actual controllers have been fulfilled on time[88].

Financial Performance - The company's revenue for Q1 2022 was ¥1,583,603,294.78, representing a decrease of 23.70% compared to the same period last year[5] - Net profit attributable to shareholders was ¥27,687,468.03, down 73.46% year-on-year[5] - Basic earnings per share decreased by 76.47% to ¥0.04[5] - Total operating revenue for Q1 2022 was CNY 1,583,603,294.78, a decrease of 23.7% compared to CNY 2,075,361,491.16 in the same period last year[23] - Net profit for Q1 2022 was CNY 24,220,336.23, a decline of 78.9% from CNY 115,290,795.53 in Q1 2021[24] Cash Flow - The net cash flow from operating activities was -¥27,887,419.95, an improvement of 72.48% compared to the previous year[5] - Cash flow from operating activities for Q1 2022 was negative CNY 27,887,419.95, an improvement from negative CNY 101,318,622.75 in Q1 2021[25] - The net cash flow from financing activities was ¥103,835,960.11, a significant increase of 1214.50% due to increased bill discounting financing[15] - The net cash flow from financing activities was 103,835,960.11, a significant improvement from -9,316,842.95 in the previous period[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥9,060,340,153.31, a decrease of 2.21% from the end of the previous year[5] - Total current assets as of March 31, 2022, amount to ¥6,156,605,848.50, a decrease from ¥6,359,118,877.14 at the beginning of the year[20] - Total current liabilities as of March 31, 2022, are ¥3,314,625,513.35, compared to ¥3,549,510,922.96 at the beginning of the year[21] - Total liabilities as of Q1 2022 were CNY 3,927,217,641.09, a decrease from CNY 4,175,018,175.08 in the previous year[24] Shareholder Information - Total number of common shareholders at the end of the reporting period is 37,475[17] - The largest shareholder, Zou Jianhan, holds 20.23% of shares, totaling 127,620,000 shares, with 95,715,000 shares pledged[17] - The second-largest shareholder, Li Wuling, holds 17.82% of shares, totaling 112,420,091 shares[17] Investment and Expenses - Investment income rose by 39.54% to ¥43,313,092.10, attributed to increased forward foreign exchange settlement gains[12] - Research and development expenses for Q1 2022 were CNY 63,821,842.75, a decrease of 25.5% compared to CNY 85,665,731.60 in Q1 2021[24] - Sales expenses for Q1 2022 were CNY 269,927,260.75, down 13.0% from CNY 309,988,037.06 in Q1 2021[24] Other Financial Metrics - The company reported a 290.85% increase in fair value changes, amounting to ¥14,395,574.75, due to effective currency risk management[12] - The company experienced a 125.54% increase in credit impairment losses, totaling -¥12,940,520.58, due to higher provisions for receivables[12] - Other comprehensive income after tax for Q1 2022 was CNY 17,176,185.57, compared to negative CNY 26,946,117.00 in Q1 2021[25] - Total equity attributable to shareholders of the parent company was CNY 4,874,852,747.55, an increase from CNY 4,828,764,373.98 in the previous year[24]

Financial Performance - The company's operating revenue for 2021 was approximately CNY 7.93 billion, representing a year-on-year increase of 12.25% compared to CNY 7.05 billion in 2020[19]. - The net profit attributable to shareholders of the listed company for 2021 was approximately CNY 458.36 million, an increase of 4.34% from CNY 439.28 million in 2020[19]. - The company reported a significant decrease of 65.66% in the net profit attributable to shareholders in the adjusted figures, compared to CNY 413.62 million in 2020[19]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, decreased by 65.66% compared to the previous year, primarily due to significant increases in raw material prices, fluctuations in the RMB to USD exchange rate, rising shipping costs, and asset impairment losses[20]. - The global health massage business achieved revenue of 5.497 billion yuan, representing a year-on-year growth of 23.81%[20]. - Revenue from the company's own health massage brand reached 2.8 billion yuan, with a year-on-year increase of 33.10%[20]. - The total assets at the end of 2021 were 9.265 billion yuan, an increase of 3.50% compared to the end of 2020[20]. - The net assets attributable to shareholders increased by 8.00% to 4.829 billion yuan at the end of 2021[20]. - The basic earnings per share for the year were 0.74 yuan, a decrease of 3.90% compared to the previous year[20]. - The diluted earnings per share remained stable at 0.68 yuan, unchanged from the previous year[20]. - The weighted average return on equity was 9.89%, down from 12.11% in the previous year[20]. - The company reported a net cash flow from operating activities of -17.52 million yuan, a significant decline of 102.44% compared to the previous year[20]. Dividend Distribution - The company plans to distribute a cash dividend of CNY 3 per 10 shares (including tax) to all shareholders, with no bonus shares issued for the year[4]. - The total distributable profit for the year is RMB 2,276,641,927.01, with cash dividends accounting for 100% of the profit distribution[135]. Business Operations - The company has not changed its major business operations since its listing, focusing on the research and sales of health-related products[18]. - The company plans to focus on core business areas, enhance technological innovation, and strengthen its own brand development while divesting non-core businesses[30]. - The company is focusing on a "product + service" model, integrating AI technology into its massage products to enhance user experience[47]. - The company is expanding its international presence with brands like "OGAWA" in international markets, "FUJI" in Taiwan, and "cozzia" in North America[94]. - The company is shifting some resources towards the development of small massage appliances for the domestic market[95]. Research and Development - The company invested 289 million CNY in R&D during the reporting period, focusing on integrating traditional Chinese medicine with modern digital technology[36]. - The company has accumulated 1,160 patents and was recognized among the top 500 private enterprises for R&D investment and invention patents in 2021[42]. - The company has a total of 931 R&D personnel, an increase of 10.70% from 841 in the previous year[61]. Market Position and Sales - The health massage segment's revenue grew by 23.81% year-on-year, accounting for 71.26% of the main business revenue[50]. - The sales volume of massage chairs reached 470,100 units, an increase of 17.50% compared to the previous year[55]. - The company has an annual production capacity of 700,000 smart massage chairs and over 17 million small massage appliances[44]. - The gross profit margin for the main business was 30.26%, down 4.33% year-on-year, primarily due to rising raw material costs[52]. - The main brand "OGAWA" continues to lead in the domestic market, with a new range of smart massage products launched to meet diverse consumer needs[45]. - Domestic sales accounted for 22.10% of total revenue, while international sales made up 77.90%, with a year-on-year growth of 11.74%[50]. Corporate Governance - The company has established a strong governance structure with independent directors and a diverse board composition[112]. - The management team includes professionals with extensive experience in their respective fields, ensuring effective leadership and operational oversight[113]. - The company is committed to maintaining transparency and accountability in its financial reporting and corporate governance practices[110]. - The company has a structured approach to corporate governance, ensuring compliance and accountability among its board members[116]. Risk Management - The company faces risks from macroeconomic fluctuations that could impact the demand for its massage products[97]. - The ongoing COVID-19 pandemic poses risks to daily activities and global supply chains, affecting the company's operations[98]. - Rising raw material and shipping costs could adversely affect the company's business if these trends continue[99]. - The company has a risk control system in place for financial derivatives trading, ensuring compliance with regulatory requirements and effective risk management[78]. Social Responsibility - The company actively engages in social responsibility, supporting pandemic prevention efforts and promoting community welfare[146]. - The company donated a total of RMB 3.6598 million in pandemic prevention materials to various organizations, including RMB 1 million specifically for a cardiac surgery fund[152]. - The company has actively participated in poverty alleviation projects, donating over RMB 2.3 million and approximately RMB 190,000 worth of books to impoverished areas[153]. Internal Controls - The company has established a scientific internal control system to effectively prevent operational risks[138]. - There were significant internal control deficiencies identified, including non-operating fund occupation amounting to RMB 61.5 million, which has been rectified[139]. - The company has implemented measures to improve internal controls and enhance the quality of information disclosure following the warning received[165]. Shareholder Information - The company reported a total of 243,483,791 shares held by directors and senior management, with no changes in shareholding during the reporting period[110]. - Major shareholders include Zou Jianhan with 20.23% (127,620,000 shares) and Li Wuling with 17.82% (112,420,091 shares) as of the end of the reporting period[187]. - The company’s share capital increased to 630,693,012 shares, with a total increase of 12,017,212 shares during the reporting period[178].

Financial Performance - The company's operating revenue for Q3 2021 was ¥1,879,421,869.91, a decrease of 4.10% compared to the same period last year[3]. - The net profit attributable to shareholders for Q3 2021 was ¥45,072,379.61, down 74.69% year-on-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥9,650,048.85, a decrease of 93.97% compared to the same period last year[3]. - The basic earnings per share for Q3 2021 was ¥0.07, a decline of 78.13% year-on-year[3]. - Total operating revenue for Q3 2021 reached CNY 5,817,702,990.64, an increase of 22.5% compared to CNY 4,746,075,693.20 in the same period last year[20]. - Net profit for Q3 2021 was CNY 333,734,093.36, representing a 5.5% increase from CNY 315,383,288.73 in Q3 2020[21]. - Operating profit for the period was CNY 383,984,181.81, a decrease of 3.4% compared to CNY 397,737,054.26 in the same quarter last year[21]. - The company reported a total comprehensive income of CNY 338,042,001.71, compared to CNY 324,005,766.65 in Q3 2020[21]. - Basic earnings per share for Q3 2021 were CNY 0.50, down from CNY 0.59 in the same quarter last year[21]. Assets and Liabilities - The total assets at the end of Q3 2021 amounted to ¥9,225,634,229.54, an increase of 2.36% from the end of the previous year[3]. - The company's total liabilities decreased slightly to CNY 4,201,679,376.77 from CNY 4,226,368,800.89 year-over-year[20]. - The total assets of the company increased to CNY 9,225,634,229.54 from CNY 9,013,244,221.32 year-over-year[20]. - Total liabilities amounted to approximately CNY 4.23 billion, a decrease of CNY 179.44 million compared to the previous period[29]. - Non-current liabilities totaled CNY 758.60 million, down from CNY 849.92 million, reflecting a reduction of CNY 91.32 million[29]. Cash Flow - The company's cash flow from operating activities for the first nine months of 2021 was -¥360,657,543.61, a decrease of 164.63% compared to the same period last year[12]. - The net cash flow from operating activities was -360,657,543.61 CNY, a decrease compared to 557,999,505.64 CNY in the previous period[24]. - Total cash inflow from operating activities amounted to 6,224,954,069.11 CNY, while cash outflow was 6,585,611,612.72 CNY[24]. - Cash flow from investment activities generated a net inflow of 193,947,201.48 CNY, contrasting with a significant outflow of 1,619,184,230.30 CNY in the previous period[25]. - The net cash flow from financing activities was -158,259,425.12 CNY, compared to a positive inflow of 1,513,062,750.22 CNY previously[25]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 30,825[14]. - The company holds 7,249,748 shares in its repurchase account, accounting for 1.15% of the total share capital[15]. - The top two shareholders, Zou Jianhan and Li Wuling, hold 20.24% and 17.83% of shares respectively, with significant portions pledged[14]. - The company has not engaged in any financing or securities lending activities among the top ten shareholders[15]. Inventory and Receivables - The company's inventory increased by 45.59% to ¥1,843,812,470.20 due to shipping disruptions and pandemic impacts[9]. - Accounts receivable increased to ¥1,371,704,285.10 from ¥1,299,597,673.94, reflecting a growth of about 5.5%[17]. - Inventory rose significantly to ¥1,843,812,470.20 from ¥1,266,464,699.48, marking an increase of approximately 45.5%[18]. Research and Development - Research and development expenses rose to CNY 207,699,090.16, compared to CNY 187,317,005.43 in Q3 2020, reflecting a focus on innovation[20]. Other Information - The company adopted new leasing standards starting January 1, 2021, impacting the recognition of lease liabilities and assets[30]. - The third quarter report was not audited, indicating that the figures may be subject to further review[31]. - The company has not disclosed specific user data or performance guidance for future quarters in the provided documents[29][30][31].

证券代码：002614 股票简称：奥佳华 公告编号：2021-47 号 债券代码：128097 债券简称：奥佳转债 奥佳华智能健康科技集团股份有限公司 关于参加 2021 年度厦门辖区上市公司 投资者网上集体接待日活动的公告 本公司及全体董事、监事、高级管理人员保证信息披露内容的真实、准确 和完整，没有虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，使广大投资者能更深入全面地了解公司 情况，奥佳华智能健康科技集团股份有限公司（以下简称"公司"）将于 2021 年 9 月 7 日（星期二）15:00-17:00 参加由厦门证监局指导，厦门上市公司协会 联合深圳市全景网络有限公司举办的"2021 年度厦门辖区上市公司投资者网上 集体接待日"活动。 本次活动将通过深圳市全景网络有限公司提供的网上平台进行，投资者可以 登录"全景网投资者互动平台"（http://ir.p5w.net）参与在线交流。届时公司高 管人员将通过网络与投资者就公司治理、经营情况、发展战略等投资者关注的问 题进行实时沟通。 出席本次投资者集体接待日活动的人员有：董事长兼总经理邹剑寒先生，副 总经理兼董事会秘书李巧巧女士，财务总 ...

Financial Performance - The company's operating revenue for the first half of 2021 reached ¥3,938,281,120.73, representing a 41.34% increase compared to ¥2,786,334,397.11 in the same period last year[22]. - Net profit attributable to shareholders was ¥266,325,928.14, a significant increase of 78.68% from ¥149,053,695.15 in the previous year[22]. - The net profit after deducting non-recurring gains and losses was ¥203,005,211.78, up 37.05% from ¥148,126,084.86 year-on-year[22]. - The basic earnings per share increased by 59.26% to ¥0.43 from ¥0.27 in the same period last year[22]. - The total revenue for the reporting period reached CNY 3.94 billion, a year-on-year increase of 41.34% driven by significant growth in health massage and health environment sectors[49]. - The company reported a total profit for the first half of 2021 of ¥330,097,601.81, compared to ¥181,963,654.18 in the same period last year, marking an increase of 81.2%[150]. - The total comprehensive income for the first half of 2021 was ¥295,604,613.53, compared to ¥133,826,627.71 in the first half of 2020, indicating a growth of 109.5%[151]. Assets and Liabilities - The total assets at the end of the reporting period were ¥9,367,494,085.76, reflecting a 3.93% increase from ¥9,013,244,221.32 at the end of the previous year[22]. - The net assets attributable to shareholders increased by 4.26% to ¥4,733,566,129.23 from ¥4,539,986,752.90 at the end of the previous year[22]. - The company's total liabilities include short-term borrowings of ¥666,481,380.10, up from ¥417,906,676.28 last year[141]. - Total liabilities increased to CNY 4,358,570,155.36, up from CNY 4,226,368,800.89, reflecting a growth of approximately 3.13%[143]. - Total equity rose to CNY 5,008,923,930.40, compared to CNY 4,786,875,420.43, marking an increase of about 4.63%[143]. Cash Flow - The company reported a net cash flow from operating activities of -¥105,984,579.43, a decrease of 123.78% compared to ¥445,724,229.73 in the same period last year[22]. - The company's cash flow remains stable and abundant, ensuring the ability to meet future convertible bond interest payments[133]. - The net cash flow from investing activities was 389,991,201.67 CNY, a recovery from a negative cash flow of -1,483,709,201.75 CNY in the first half of 2020[157]. - The net cash flow from financing activities was -195,915,319.04 CNY, a decline from a positive cash flow of 1,473,993,598.06 CNY in the same period last year[157]. Research and Development - The company has accumulated 1,093 patents as of the end of the reporting period, showcasing its commitment to R&D innovation[35]. - The company’s R&D expenses were CNY 140.30 million, a slight increase of 2.73% compared to the previous year, indicating ongoing investment in technology innovation[50]. - Research and development expenses for the first half of 2021 were ¥140,296,585.54, slightly up from ¥136,572,816.68 in the first half of 2020[148]. Market and Product Development - The flagship product, the OG-8598 AI massage robot, won the "AWE Excellent Product Award" for two consecutive years[36]. - The company operates under multiple brands, with "OGAWA" ranking among the top two health brands in Southeast Asia and "FUJI" being the second in Taiwan[39]. - The health environment segment achieved a rapid growth of 54.21% during the reporting period, contributing to the overall revenue increase[53]. - The company has established a comprehensive product and service model, integrating AI technology into its massage products[40]. Shareholder Information - The annual shareholders' meeting had an investor participation rate of 42.48%[78]. - The company plans not to distribute cash dividends or issue bonus shares for the half-year period[80]. - Major shareholders include Zou Jianhan with 20.24% and Li Wuling with 17.83% of total shares[113]. - The total number of shares increased to 630,588,790, with a net increase of 11,912,990 shares during the reporting period[106]. Risks and Challenges - The company faces risks from macroeconomic fluctuations, which could impact its operations if the global economy experiences significant downturns[73]. - The ongoing COVID-19 pandemic continues to pose risks to the company's operations and supply chain[74]. - Rising prices of raw materials and shipping costs have been identified as potential risks that could adversely affect the company's operations[75]. Corporate Governance - The financial statements are prepared in accordance with the accounting standards issued by the Ministry of Finance and reflect the company's financial position as of June 30, 2021[186]. - The company’s consolidated financial statements include all subsidiaries under its control, reflecting the overall financial status and performance of the group[192]. - The company has not disclosed specific user data or future guidance in the provided documents[182].

奥佳华智能健康科技集团股份有限公司 2021 年第一季度报告 1 奥佳华智能健康科技集团股份有限公司 2021 年第一季度报告 公告编号：2021-31 号 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人邹剑寒、主管会计工作负责人苏卫标及会计机构负责人(会计主 管人员)廖晶声明：保证季度报告中财务报表的真实、准确、完整。 2 奥佳华智能健康科技集团股份有限公司 2021 年第一季度报告 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | | --- | --- | --- | --- | --- | | 营业收入（元） | 2,069,687,733.48 | 1,021,166,229.13 | | 102.68% | | 归属于上市公司股东的净利润（元） | 105,664,402.70 | -31,23 ...